Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 8—August 2005
Research

Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use

Conan MacDougall*, Spencer E. Harpe*, J. Patrick Powell*, Christopher K. Johnson†, Michael B. Edmond*, and Ron E. Polk*Comments to Author 
Author affiliations: *Virginia Commonwealth University, Richmond, Virginia, USA; †Idaho State University, Boise, Idaho, USA

Main Article

Table 3

Longitudinal GEE models*

Drug FQ-R P. aeruginosa
 MRSA
Coefficient p value Coefficient p value
Total FQ
Previous year's resistance 0.875 <0.001 0.804 <0.001
Total FQ use 0.002 0.883 0.025 0.155
Time -0.312 0.554 1.04 0.040
Constant 6.75 0.001 4.61 0.058
Levofloxacin
Previous year's resistance 0.868 <0.001 0.818 <0.001
Levofloxacin use 0.005 0.548 0.012 0.033
Time -0.317 0.579 1.04 0.041
Constant 6.78 0.001 6.38 0.001
Ciprofloxacin
Previous year's resistance 0.866 <0.001 0.845 <0.001
Ciprofloxacin use -0.018 0.226 -0.004 0.848
Time -0.393 0.475 0.991 0.079
Constant 8.185 <0.001 6.55 0.033

*Association of fluoroquinolone and pathogen resistance over time controlling for prior year resistance. GEE, generalized estimating equations; FQ-R P. aeruginosa, fluoroquinolone-resistant Pseudomonas aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus.

Main Article

Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external